Phreesia (PHR) Scheduled to Post Quarterly Earnings on Monday

Phreesia (NYSE:PHR - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, December 9th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Phreesia has set its FY 2025 guidance at EPS.Parties interested in registering for the company's conference call can do so using this link.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.06. The business had revenue of $102.12 million during the quarter, compared to the consensus estimate of $101.76 million. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Phreesia Price Performance

Shares of PHR stock traded up $0.07 during trading hours on Monday, reaching $21.10. The company's stock had a trading volume of 338,668 shares, compared to its average volume of 446,035. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.03. Phreesia has a fifty-two week low of $14.55 and a fifty-two week high of $29.16. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -11.72 and a beta of 0.94. The firm's 50 day simple moving average is $20.43 and its 200-day simple moving average is $21.84.

Insider Buying and Selling

In other news, insider Yvonne Hui sold 2,791 shares of the business's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.92, for a total value of $58,387.72. Following the transaction, the insider now directly owns 27,228 shares of the company's stock, valued at $569,609.76. The trade was a 9.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP David Linetsky sold 1,716 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total value of $39,897.00. Following the completion of the transaction, the senior vice president now directly owns 203,318 shares in the company, valued at approximately $4,727,143.50. This trade represents a 0.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,997 shares of company stock valued at $667,943 over the last ninety days. 5.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PHR. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 target price on shares of Phreesia in a research report on Thursday, September 5th. Royal Bank of Canada reissued a "sector perform" rating and issued a $23.00 price objective on shares of Phreesia in a research note on Friday, September 27th. Robert W. Baird upped their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock an "outperform" rating in a report on Friday, September 6th. Canaccord Genuity Group reissued a "buy" rating and set a $34.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Finally, JPMorgan Chase & Co. boosted their price objective on Phreesia from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Monday, September 9th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Phreesia has a consensus rating of "Moderate Buy" and a consensus target price of $29.42.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.